chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Three days after the vaccine I started to have extreme fatigue. One week after that I started to have heart palpitations and I called my doctor. I went to the ER and I had ST elevations in my Stemi. I was in the hospital one night. I was given a Heparin drip and aspirin. I was discharged with an unexplained ST elevation and MI. I normally run Marathons and I have been having a lot of problems since the vaccine. I had extreme fatigue two weeks after the shot and I was unable to get out of bed. I am still having Palpitations every day intermittently after three weeks. I am still extremely fatigued. When I was getting the scans I could hear my arm vibrating.
Hives. Initially itchiness on palms of hands then itchiness throughout body. The past 1-2 weeks the itchiness/hives are most intense around neck, shoulders, and upper back. There is itchiness on feet. Allergy medicine works but without medicine, the hives and itchiness comes back.
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose 01/08/21pfizer,Lot#EL3248 2nd dose 01/29/21,Pfizer,lot#EN5318 Diagnosed covid positive:08/02/21 Symptom onset:07/31/21 Exposure:unknown Symptoms:cough, fatigue, nausea, diarrhea.
Within about 5 hours of the vaccine, started to feel skin sensitivity all over my body.  It felt like every pore on my body was open and hyper sensitive to touch.  My scalp was very sensitive to touch and there was a strange sensation when my clothes touched my body- I've never been hyper sensitive like this before. Within about 12 hours, developed a fever, chills and inability to get warm.   Symptoms persisted for about 36 hours.
This case was reported by a other health professional via sales rep and described the occurrence of hives in a 62-year-old male patient who received SHINGRIX for prophylaxis. On 6th September 2018, the patient received the 2nd dose of SHINGRIX .5 ml. In September 2018, less than a week after receiving SHINGRIX, the patient experienced hives, chills, fever and diarrhea. In September 2018, the outcome of the hives, chills, fever and diarrhea were recovered/resolved. It was unknown if the reporter considered the hives, chills, fever and diarrhea to be related to SHINGRIX. Additional details were provided as follows: The patient received the SHINGRIX on Thursday. The patient had hives, rigorous chills, fever and diarrhea. The patient went to the emergency room. It was stated that, by Monday the patient was okay. The reporter agreed for follow up.
This case was reported by a pharmacist via call center representative and described the occurrence of appendicitis in a elderly male patient who received SHINGRIX for prophylaxis. Concurrent medical conditions included knee pain (presented before receiving SHINGRIX). On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, unknown after receiving SHINGRIX, the patient experienced appendicitis (serious criteria GSK medically significant), injection site pain, bladder disorder and constipation. On an unknown date, the outcome of the appendicitis, injection site pain, bladder disorder and constipation were unknown. It was unknown if the reporter considered the appendicitis, injection site pain, bladder disorder and constipation to be related to SHINGRIX. Additional details were reported as follows: This case was reported via online chat. The age at vaccination was not reported. The patient had a knee replacement surgery after receiving SHINGRIX. After vaccination, the patient experienced post-surgical constipation, appendicitis, and bladder complications. After the patient was transferred to a Medical Engagement Specialist, he experienced injection site pain after vaccination. The reporter was not sure if the patient's surgery or experiences after surgery were reportable adverse events. The reporter had given consent to follow up.
11/10 vaccination. 11/11 Woke up with body aches, HA, brain fog; 8AM. 11/12 I felt fine. 11/26-27th, I notices on my R hip bone skin rash. I do have eczema so I didn't pay too much attention to it. 11/28 flu vaccine administered. 12/1/2021 rash looked just like when I had had shingles before and I called the doctor. I was prescribed anti-viral. Diagnosed Shingles. After 2nd dose of Moderna, I had fever. About a week after, I got a lot of side affects with cold sores on my lips. *2018 shingles *vaccination lot card hard to read.
Sore throat, high fever, chills, malaise, headache, arthralgia, nausea/dizziness.
pt recv vax 8JAN97 & 9JAN97 pt exp numbness of the rt ear;
Different vaccine administered; This spontaneous case was reported by a consumer and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Different vaccine administered) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    Concurrent medical conditions included Congestive heart failure, BP raised, Diabetes, Allergy and Stomach ache.   On 15-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 09-Jun-2021, the patient received second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 09-Jun-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Different vaccine administered). The patient was treated with PARACETAMOL (TYLENOL) (oral) for Fever, at a dose of 1 dosage form. At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (Different vaccine administered) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 24-Mar-2021, SARS-CoV-2 test: positive (Positive) positive. On an unknown date, Cardiovascular examination: unknown (Inconclusive) unknown.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No concomitant medication was reported.    No treatment information was provided.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 06-Aug-2021: event outcome updated.
Began with sore, itching throat and headache. On 10/26, 2016, had nausea, vomiting, shaking, fever of 102 degrees, aching joints.
experiencing seasonal allergies after receiving the second dose in the series; This spontaneous case was reported by a consumer and describes the occurrence of SEASONAL ALLERGY (experiencing seasonal allergies after receiving the second dose in the series) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Pollen allergy (seasonal allergies to pollen), Seasonal allergy (seasonal allergies to trees) and Grass allergy (seasonal allergies to grass). Concomitant products included CETIRIZINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (ZYRTEC-D) for Seasonal allergy, ASCORBIC ACID (VITAMIN C ACID) and ZINC for an unknown indication.   On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 23-Apr-2021, the patient experienced SEASONAL ALLERGY (experiencing seasonal allergies after receiving the second dose in the series). At the time of the report, SEASONAL ALLERGY (experiencing seasonal allergies after receiving the second dose in the series) had not resolved.            No Treatment information provided
Seriousness criteria other medically significant (OMIC). Initial report received on 11/6/06 from the pt. An 18 year old male pt, with no concurrent illnesses, and a past medical history of TMJ (temporamandibular joint disorder), had received a first dose of Menactra in Sept 2006. The day of vaccination, lot number, route and site of administration were not reported. Two weeks post immunization, the pt developed blurred vision in the right eye, and some complaint of headache. The pt exhibited no other symptoms. On 11/3/06, the pt was evaluated by an ophthalmologist and diagnosed with possible optic neuritis. The pt has been scheduled for some tests, but the name and date of the tests were not reported. The contact information fir the ophthalmologist was provided. At the time of this report, the pt had not recovered.
initial arm soreness, followed by extreme fever of 103.9 on set hour 8 and lasting for 12+ hours.  Roughly hour 28 extreme lung pressure, new bruising and patching red dots on palms of hands.  A phone call was made to a Covid help line and determined an ER visit was needed ASAP.  ER visit determined an extremely elevated INR, but chest xray was clear.  Toradol injection given after it was determined it was an inflammatory response to the vaccine centered in the tissue/muscles between the ribs.
Information has been received from a registered nurse referring to an unspecified patient of unknown gender and age. Information about concurrent condition, drug reactions/allergies and medical history was unknown. Concomitant therapies included sterile diluent (manufacturer unknown). On 14-AUG-2017, the patient was vaccinated with improperly stored doses of VARIVAX (Lot # N001530, expiration date 13-JAN-2019, strength, dose and route unknown) for prophylaxis, the sterile diluent (manufacturer unknown) (lot# and expiration date unknown) used to reconstitute the vaccine above was properly stored. No adverse effects were reported. The vaccines were exposure at the temperature of 12.4 Fahrenheit (6 to 14 Fahrenheit) for 15 hours and 45 minutes. There was no previous temperature excursion. A data logger was involved. This is one of several reports from the same reporter.; Sender's Comments: US-009507513-1708USA008578: US-009507513-1709USA007601: US-009507513-1709USA007602: US-009507513-1709USA007603: US-009507513-1709USA007604: US-009507513-1708USA007019:
At 4:30 PM patient had a generalized tonic -clonic seizure and fever of 103. Seizure lasted 3-4 minutes and was postictal for 45-50 mins. Was transferred by EMS to ER. In ER  temp was 100.2. her physical exam waas normal. Labs: WBC8.63k; Hgb 12.2; Plts 374.2k ; neut 60 %; Urinanalysis  was negative; procalcitonin .10
I had a very sore arm for several days. The morning after the shot I had a headache and body aches. I was dizzy and by the afternoon had a fever of 99.8. I had to take a nap that lasted for two hours. The next day I was still somewhat weak and had to somewhat curtail my usual activities.
her blood platelet count was lower; Lipase count was up; she has muscle, pain joint; she has muscle, pain joint; This is a spontaneous report from a contactable consumer (patient). A 73-year-old female patient received bnt162b2 ( PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as single dose for COVID-19 immunization. Medical history included osteoarthritis from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. The patient reported that she took the Pfizer COVID vaccine and her blood platelet count was lower than usual. Lipase count was up and she has muscle, pain joint. Outcome of events was unknown. Events reported as non-serious.  Information on the lot/batch number has been requested.
This case was reported by a physician via sales rep and described the occurrence of pain in arm in a adult patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, unknown after receiving SHINGRIX, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was unknown. It was unknown if the reporter considered the pain in arm to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but it was selected as adult as per the vaccine indication. The reporter stated that 1 in 10 patients he gives SHINGRIX and has severe arm pain. The reporter did not agree to follow up.
pt devel an urticarial rash following vax; tx included DPH; DPH was tapered, however, p/several days, rash returned & pt was treated w/DPH x 2 wks; rash was not observed by MD;
Accidentally discovered on March 25, 8 days after the 1st shot, after feeling a slight pain when it was accidentally touched. Upon checking, there's a skin rash - Patchy reddish, elevated, hard and warm to touch, palm-size very close to the injection site. Didnt feel any itchiness, maybe because I had Zyrtec a day before (nasal allergy)?  March 26 - arms feels heavy, not painful but bothersome, slightly itchy, reduced skin redness
blood clots in his lungs; shortness of breath; This is a spontaneous report from a Pfizer- sponsored program from a contactable consumer reported for self. This male patient of unspecified age received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) at single dose on an unspecified date for COVID-19 immunization. Medical history and concomitant medication were not reported. Patient felt so out of it after receiving second dose. He went to the hospital a week after second dose and was diagnosed with blood clots in his lungs. He had shortness of breath as well. He was on a blood thinner now. The outcome of events was unknown.  The information on the lot/batch number has been requested.
Bleeding at 31 weeks pregnancy. Emergency cesarean as a result when baby wasn?t moving well. Placenta full of blood clots. Patient told placenta had detached during pregnancy. Patient states OB said unknown why this happened. Baby was very small for gestation and died in NICU at 7 days old. Patient told from necrotizing enter colitis.
All 3 shots created strong immune response in my eyes that required a steroid eye drop treatment. I was prescribed prednisone and Eyesuvis drops.
PATIENT RECEIVED COVID-19 PFIZER VACCINE Dose 1 date: 12/29/2020 AND  Dose 2 date: 1/19/2021. PT TESTED POSITIVE TO COVID ON 8/16/21
I tested positive for COVID-19 on 12/14/22. I had a congestion, postnasal drip, fever, body aches, and scratchy throat. I contacted my doctor but was not prescribed medication. I took over-the-counter medication, FLONASE, and TYLENOL. These symptoms lasted until 1/2/23. I am feeling much better now, but a still having postnasal drip. Other than that, I am good.
Her arm hurts off and on since she received the vaccine/can pinpoint where the injection was given; This is a spontaneous report received from contactable reporter(s) (Other HCP) from a sales representative. The reporter is the patient.  An adult female patient (not pregnant) received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION SITE PAIN (non-serious), outcome "unknown", described as "Her arm hurts off and on since she received the vaccine/can pinpoint where the injection was given". It was unknown if therapeutic measures were taken as a result of vaccination site pain.  Additional information: Her arm hurts off and on since she received the vaccine. She can pinpoint where the injection was given.  The information on the batch/lot number for bnt162b2 omi xbb.1.5 has been requested and will be submitted if and when received.
Information has been received from a physician concerning his wife who was vaccinated with a dose of varicella-zoster virus vaccine live.  Within the last month, in July 2006, the patient experienced a varicella like rash.  Unspecified medical attention was sought.  There was no product quality complaint involved.  Additional information has been requested. This is in follow-up to report(s) previously submitted on 5/8/2006.  Information has been received from a physician concerning his 60 year wife with no known medical history who was vaccinated in the left deltoid with a first dose of ZOSTAVAX (Merck) (dilulent Lot # 0581F).  There was no illness at the time of vaccination.  Within the last month, in July 2006, the patient experienced a varicella like rash.  Unspecified medical attention was sought.  Additional information from the physician and a registered nurse indicated the patient was vaccinated on 12-JUL-2006 and the next day on 13-JUL-2006 she developed a rash of 5 small pox on her right lower waist and abdomen.  Subsequently the patient recovered and was "doing fine".  No laboratory tests were performed.  There was no product quality complaint involved.  No further information is expected.
This spontaneous report as received from a physician via a company representative refers to a female patient of unknown age. The patient's medical history, drug reactions, allergies and concomitant medications were not reported. On 21-NOV-2012, the patient was vaccinated with a first dose of GARDASIL lot# 1696AA (dose, route of administration and expiration date were not reported). Then on 08-APR-2013, the patient was vaccinated with a second dose of GARDASIL lot # 0636AE (dose, route of administration and expiration date were not provided). In July 2013, the patient was diagnosed with lupus (systemic lupus erythematosus). At the reporting time, the outcome of the event was unknown. The relatedness between the event and GARDASIL was not reported. Upon internal review, the event of systemic lupus erythematosus was considered to be medically significant. Additional information has been requested.
COVID; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID) in a 51-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis.    Concurrent medical conditions included Psoriatic arthritis.   On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 29-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to at an unspecified dose. In January 2022, the patient experienced COVID-19 (COVID). In 2022, COVID-19 (COVID) had resolved.            No concomitant and treatment information was provided.  The reporter's causality for the event of covid with Humira was no reasonable possibility.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in  CC: This spontaneous case concerns a 51-year-old, male patient with a concurrent condition of psoriatic arthritis treated with adalimumab, who experienced an unexpected, non-serious AESI COVID-19 the following month after receiving a 3rd dose of mRNA-1273 vaccine. Vaccination history included a 2-dose primary series of mRNA-1273 vaccine, given 28 days apart. Further details on the medical history, clinical course, diagnostics, and treatments were not reported. Patient's underlying psoriatic arthritis and treatment with adalimumab could predispose him to various infectious diseases. The benefit-risk relationship of mRNA-1273 is not affected by this report. Event's seriousness assessed based on medical judgement and the available information.   Most recent FOLLOW-UP information incorporated above includes: On 23-Mar-2022: Follow-up information included event outcome updated, new dosage regimen and batch number added for Humira suspect.; Sender's Comments: This spontaneous case concerns a 51-year-old, male patient with a concurrent condition of psoriatic arthritis treated with adalimumab, who experienced an unexpected, non-serious AESI COVID-19 the following month after receiving a 3rd dose of mRNA-1273 vaccine. Vaccination history included a 2-dose primary series of mRNA-1273 vaccine, given 28 days apart. Further details on the medical history, clinical course, diagnostics, and treatments were not reported. Patient's underlying psoriatic arthritis and treatment with adalimumab could predispose him to various infectious diseases. The benefit-risk relationship of mRNA-1273 is not affected by this report. Event's seriousness assessed based on medical judgement and the available information.
Patient developed HSP on 12-18-14. No UA or kidney findings as of 12-23-14. BP NL. He did also have viral illness 2 wks prior to rash w/ fever then.
Patient has a red, very inflamed, hot arm. She also has a fever with chills and her back hurts. She may seek a doctors care later today.
2 small solid knots of 0.25 bean sized, on bilateral groin area without tenderness. Status 10 days after 12 months vaccinations.
Experienced mild flu-like symptoms; including chills, fatigue, exhaustion, some nausea and general unwell feeling. Onset was approx 30hrs after receiving 2nd dose.
FEVER; This spontaneous report received from a parent concerned a male of unspecified age. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1802072, and batch number: 1802072) dose was not reported, once a total administered on 10-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 11-MAR-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 100.5 (units unspecified). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from fever. This report was non-serious.
This spontaneous report was received on 12-OCT-2016 from a licensed practical nurse who reported that multiple unspecified patients (gender and age not specified) received improperly stored vaccines on either 11-OCT-2016 or 12-OCT-2016. The patients' pertinent medical history, current conditions and concomitant medications were not reported. On 11-OCT-2016 or 12-OCT-2016, the patients received improperly stored VAQTA (Lot number M015290, expiration date 20-SEP-2017) (Lot number M032492, expiration date 02-MAR-2018). Temperature was reported as 34.8 degrees Fahrenheit. Time frame was reported as 5 hours 22 minutes. The vaccines were reported as administered. There was no previous temperature excursion. The Call was because of data logger. No adverse effects were reported. No additional information was available. No product quality complaint involved. This is one of several reports received from same source. Additional information has been requested.
Pt's husband called pharmacy to report pt had a "softball sized lump" that was "red and warm" and "getting bigger."
Less than 48 hours after receiving my first dose of Pfizer Covid-19 vaccine, I developed nerve pain in my left leg.  I experienced signifcant pain upon standing from a prone/supine or sitting position.  I have seen an Urgernt care NP who said it was muscular and prescribed flexeril (did not help), then a physican who prescribed a steroid for siatica (did not help) and then I went to PT and have been doing the prescribed exerices.  Over time, the condition has improved, but I still experience pain when sitting along oustside of left leg I recognize the timing of this injury could be completely coincidentital, but I am reporting it in the event that others have had a simiiar experience and a pattern can be identified.
left great toe pain and swelling, which started a few hours after receiving vaccine. He saw another provider who diagnosed him with acute gout. He has no prior history of gout